ciglitazone has been researched along with Disease Models, Animal in 18 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock." | 7.74 | Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008) |
| "Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control." | 3.77 | Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. ( Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y, 2011) |
| "Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock." | 3.74 | Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008) |
| "Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling." | 1.35 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. ( Gangireddy, SR; Hogaboam, CM; Hu, B; Keshamouni, VG; Milam, JE; Phan, SH; Reddy, RC; Standiford, TJ; Thannickal, VJ, 2008) |
| " TZDs were first used as orally bioavailable insulin-sensitizing agents." | 1.32 | Thiazolidinedione inhibition of peritoneal inflammation. ( Chao, VA; Hornung, D; Taylor, RN; Vigne, JL; Wallwiener, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC | 1 |
| Cawthorne, MA | 1 |
| Cottam, GP | 1 |
| Duff, PT | 1 |
| Haigh, D | 1 |
| Hindley, RM | 1 |
| Lister, CA | 1 |
| Smith, SA | 1 |
| Thurlby, PL | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Otto, S | 1 |
| Jaeger, K | 1 |
| Kolodgie, FD | 1 |
| Muehlstaedt, D | 1 |
| Franz, M | 1 |
| Bischoff, S | 1 |
| Schubert, H | 1 |
| Figulla, HR | 1 |
| Virmani, R | 1 |
| Poerner, TC | 1 |
| Wuertz, BR | 1 |
| Darrah, L | 1 |
| Wudel, J | 1 |
| Ondrey, FG | 1 |
| Chima, RS | 1 |
| Hake, PW | 1 |
| Piraino, G | 1 |
| Mangeshkar, P | 1 |
| Denenberg, A | 1 |
| Zingarelli, B | 1 |
| Rhee, CK | 1 |
| Lee, SY | 1 |
| Kang, JY | 1 |
| Kim, SJ | 1 |
| Kwon, SS | 1 |
| Kim, YK | 1 |
| Park, SH | 1 |
| Hofnagel, O | 1 |
| Engel, T | 1 |
| Severs, NJ | 1 |
| Robenek, H | 1 |
| Buers, I | 1 |
| Yokoyama, Y | 1 |
| Xin, B | 1 |
| Shigeto, T | 1 |
| Mizunuma, H | 1 |
| Hornung, D | 1 |
| Chao, VA | 1 |
| Vigne, JL | 1 |
| Wallwiener, D | 1 |
| Taylor, RN | 1 |
| Woerly, G | 1 |
| Honda, K | 1 |
| Loyens, M | 1 |
| Papin, JP | 1 |
| Auwerx, J | 1 |
| Staels, B | 1 |
| Capron, M | 1 |
| Dombrowicz, D | 1 |
| Hammad, H | 1 |
| de Heer, HJ | 1 |
| Soullié, T | 1 |
| Angeli, V | 1 |
| Trottein, F | 1 |
| Hoogsteden, HC | 1 |
| Lambrecht, BN | 1 |
| Ward, JE | 1 |
| Fernandes, DJ | 1 |
| Taylor, CC | 1 |
| Bonacci, JV | 1 |
| Quan, L | 1 |
| Stewart, AG | 1 |
| Wohlfert, EA | 1 |
| Nichols, FC | 1 |
| Nevius, E | 1 |
| Clark, RB | 1 |
| Stengel, PW | 1 |
| Zeckner, DJ | 1 |
| Guo, WK | 1 |
| Wolos, JA | 1 |
| Snyder, DW | 1 |
| Milam, JE | 1 |
| Keshamouni, VG | 1 |
| Phan, SH | 1 |
| Hu, B | 1 |
| Gangireddy, SR | 1 |
| Hogaboam, CM | 1 |
| Standiford, TJ | 1 |
| Thannickal, VJ | 1 |
| Reddy, RC | 1 |
| Dahten, A | 1 |
| Koch, C | 1 |
| Ernst, D | 1 |
| Schnöller, C | 1 |
| Hartmann, S | 1 |
| Worm, M | 1 |
| Malamas, MS | 1 |
| Sredy, J | 1 |
| McCaleb, M | 1 |
| Gunawan, I | 1 |
| Mihan, B | 1 |
| Sullivan, D | 1 |
| Chang, AY | 1 |
| Wyse, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
18 other studies available for ciglitazone and Disease Models, Animal
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; | 1994 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A novel polymer-free ciglitazone-coated vascular stent: in vivo and ex vivo analysis of stent endothelialization in a rabbit iliac artery model.
Topics: Animals; Cholesterol; Disease Models, Animal; Drug-Eluting Stents; Endothelial Cells; Iliac Artery; | 2016 |
Thiazolidinediones abrogate cervical cancer growth.
Topics: Animals; Cell Differentiation; Cell Proliferation; Complement Factor D; Disease Models, Animal; Fema | 2017 |
Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.
Topics: Animals; Blood Glucose; Chemokines; Cytokines; Disease Models, Animal; Immunohistochemistry; Inflamm | 2008 |
Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Provocation T | 2009 |
SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Cells, Cultured; Chemokine CXCL16 | 2011 |
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascites | 2011 |
Thiazolidinedione inhibition of peritoneal inflammation.
Topics: Animals; Chemokine CCL5; Disease Models, Animal; Endometriosis; Female; Interleukin-1; Leukocyte Cou | 2003 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation | 2003 |
Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma.
Topics: Anilides; Animals; Asthma; Cell Movement; Cytokines; Dendritic Cells; Disease Models, Animal; Eosino | 2004 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; | 2006 |
Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.
Topics: Animals; CD4 Antigens; Disease Models, Animal; Graft vs Host Disease; Interleukin-2 Receptor alpha S | 2007 |
Methacholine-induced pulmonary gas trapping in a mouse model of allergic asthma: effect of inhaled budesonide and ciglitazone.
Topics: Administration, Inhalation; Airway Obstruction; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hy | 2008 |
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Differentiation; Cell Division; Cells, Culture | 2008 |
Systemic PPARgamma ligation inhibits allergic immune response in the skin.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models, | 2008 |
Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Hypoglycemic Agen | 2001 |
The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Blood Glucose; Disease Models, Animal; Glycolysis; H | 1988 |